Now is the time to evaluate how pharmaceutical antitrust enforcement will impact your business over the next year!

Don’t miss the opportunity on February 17 and 18 to learn from the pharmaceutical industry’s leading in-house counsel, government regulators, and expert attorneys at ACI’s 5th Annual Counsel Forum on Pharmaceutical Antitrust in New York, NY.  Hear how to successfully tackle the most complex antitrust issues currently facing brand name and generic pharmaceutical manufacturers, including -- Reverse settlement payment agreements, Mergers & acquisitions, Product migration, authorized generics and citizens petitions, Pricing, distribution and related Robinson-Patman issues.

The principal area of concern for pharmaceutical drug manufacturers right now is increased government enforcement stemming from reverse settlement payment agreements, pricing and distribution tactics, and strategic life cycle management strategies.

Recent high-profile pharmaceutical mergers and a new convergence of antitrust authorities, both in the U.S. and abroad, have many within the industry contemplating how emerging enforcement trends will ultimately impact government activity in this area, both in the U.S. and abroad.

With new leadership at the helm at both the FTC and DOJ Antitrust Division, it is clear that a closer alignment is being forged between the two agencies, both of which have named pharmaceutical antitrust enforcement as a continued priority. The DOJ has assumed a new position on enforcement under Section 2 under the Sherman Act. This coupled with recent activity by the FTC which has focused on single firm conduct eaves many in the industry desperately trying to determine how actions taken by two agencies will impact the pharmaceutical industry as a whole.

The timing for this program couldn’t be better as antitrust counsel stay up-to-speed on what the current status of the law is while also monitoring legislative and regulatory enforcement initiatives that could be impacting on the legal advice they render to clients and provide as in-house counsel.

Pharma Antitrust Master Class